Oxford Nanopore Technologies cancer research media tool kit

Introduction to our work in cancer research

The genetic underpinnings of cancer are diverse and many types of genomic aberration — from SNVs to SVs, fusion transcripts, and epigenetic modifications (e.g. DNA/RNA methylation) — can fuel or signal disease. As a result, researchers have traditionally relied on multiple techniques to identify and analyse different forms of cancer.

Nanopore sequencing is disrupting that model by delivering a streamlined and rapid solution for complete characterisation of cancer samples with the potential to be deployed in handheld devices near to the sample. The technology combines many new features in DNA analysis, sequencing any length of DNA fragment, including ultra-long reads in excess of 4 Mb, spanning complex structural variants, including DNA/RNA methylation, and achieving real-time results.

Recent announcements

Cancer cells dividing

American Association of Cancer Research: Oxford Nanopore showcases breakthrough technology to generate most comprehensive insights into cancer genomes

MinION Mk1B close-up

Oxford Nanopore and 4bases announce collaboration to combine nanopore sequencing devices and 4bases kits to support rapid, high-accuracy analyses in human and cancer genetics

Cancer animation

Oxford Nanopore Technologies and Cyclomics begin developer testing on non-invasive method for accurate and fast detection of molecules associated with cancer

Get in touch with our media team

Alex Doniach, Director of Corporate Communications

Victoria Barrie, Associate Director, Strategic Communications and Corporate Affairs

Explore our cancer research application page


White paper: Accelerating cancer research through comprehensive genomic analysis

Workflow: Characterising structural variants in FFPE cancer research samples

More resources